 |
News
feed |
| |
We are inviting expressions of interest from
organisations who wish to commission a news feed for their website
(Editor) |
| |
|
|
New
viral video tackles diabetes bullies |
| |
A short, gritty video called ‘Setting
the record straight’, to show schoolchildren and young people about Type 1 diabetes (Diabetes, UK) |
| |
|
|
Novo
diabetes drug tops older medicine at two years |
| |
Novo Nordisk A/S's experimental diabetes drug
liraglutide was significantly better at helping patients control
blood sugar than an older common medicine after two years of treatment,
according to data from a clinical trial (Reuters) |
| |
|
|
Two-year
data reveal sustained glycemic improvements with liraglutide |
| |
Liraglutide monotherapy for two years was associated
with significant, sustained improvements in glycemic control and
body weight compared with glimepiride monotherapy, according to
new results of the LEAD-3 trial (Endocrine Today) |
| |
|
|
PAD
prevalent among patients with diabetes, metabolic syndrome |
| |
Researchers are trying to find better PAD diagnostic
tests, imaging techniques and therapeutic approache (Endocrine
Today) |
| |
|
|
Diamy
Phase III study approved for younger patients in the US |
| |
Diamyd Medical reported today that the company
has received approval from the US Food and Drug Administration,
FDA, to include children with type 1 diabetes from 10 years of
age in the company's Phase III study with the diabetes vaccine
(Diamyd Medical) |
| |
|
|
A
Randomized Trial of Therapies for Type 2 Diabetes and Coronary
Artery Disease |
| |
Overall, there was no significant difference
in the rates of death and major cardiovascular events between patients
undergoing prompt revascularization and those undergoing medical
therapy or between strategies of insulin sensitization and insulin
provision (NEJM, USA) |
| |
|
|
Diabetes
with Coronary Disease |
| |
A Moving Target amid Evolving Therapies? (NEJM,
USA) |
| |
|
